For research use only. Not for therapeutic Use.
Revefenacin（Cat No.:I009017）is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by inhibiting the muscarinic M3 receptors in the airways, leading to bronchodilation and improved airflow. Administered once daily via nebulization, Revefenacin helps to relieve symptoms like shortness of breath and wheezing, making it easier for COPD patients to breathe. Its prolonged action and suitability for nebulized delivery make it particularly beneficial for patients who have difficulty using inhalers, offering improved lung function and enhanced quality of life.
| Catalog Number | I009017 |
| CAS Number | 864750-70-9 |
| Synonyms | Revefenacin; TD-4208; TD 4208; TD4208; GSK-1160724; GSK1160724; GSK 1160724.;1-(2-(4-((4-Carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl N-((1,1/’-biphenyl)-2-yl)carbamate |
| Molecular Formula | C35H43N5O4 |
| Purity | 98% |
| Target | muscarinic receptor antagonist |
| Target Protein | |
| Solubility | Soluble in DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | Ki: 0.42 nM (M1), 0.32 nM (M2), 0.18 nM (M3), 0.56 nM (M4), 6.7 nM (M5) |
| IUPAC Name | [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate |
| InChI | InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43) |
| InChIKey | FYDWDCIFZSGNBU-UHFFFAOYSA-N |
| SMILES | CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N |
| Reference | </br>1:Pulido-Rios MT, McNamara A, Obedencio GP, Ji Y, Jaw-Tsai S, Martin WJ, Hegde SS. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013 Aug;346(2):241-50. doi: 10.1124/jpet.113.203554. Epub 2013 May 17. PubMed PMID: 23685545.</br>2: Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17. doi: 10.1016/j.pupt.2012.12.006. Epub 2012 Dec 27. Review. PubMed PMID: 23274274. |
